{"entity":{"id":"nct04153734","kind":"trial","name":"Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC","aka":["Evolution"],"tldr":"A phase 2 trial of pembrolizumab, carboplatin, pemetrexed and nab-paclitaxel in lung cancer, run by Kobe Minimally Invasive Cancer Center, not yet recruiting.","summary":"Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC is a phase 2, interventional study registered as NCT04153734 by Kobe Minimally Invasive Cancer Center, with a registry enrolment figure of 21 participants, started 2019-12-01 and due to reach its primary completion in 2021-11-30. Interventions recorded: Pembrolizumab; Cis Platinum; Carboplatin; Pemetrexed; nab paclitaxel. Conditions listed: Locally Advanced Non-small Cell Lung Cancer. Primary outcome: 2-year PFS rate. Lung eligibility wording from the registry: \"Histologically confirmed NSCLC\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT04153734","url":"https://clinicaltrials.gov/study/NCT04153734"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["stage-iii-unresectable-nsclc"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["pembrolizumab","carboplatin","pemetrexed","nab-paclitaxel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04153734","phase":"2","setting":"Pembrolizumab + Platinum Doublets Without Radiation for Patients With PD-L1 ≥50% Locally Advanced Non-small Cell Lung Cancer: a Multicenter Prospective Single Arm Phase II Study","sponsor":"Kobe Minimally Invasive Cancer Center","enrolled":21,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04153734/","neighbours":{"cancer":[{"id":"stage-iii-unresectable-nsclc","kind":"cancer","name":"Unresectable stage III non-small-cell lung cancer","route":"/cancers/stage-iii-unresectable-nsclc/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"nab-paclitaxel","kind":"drug","name":"Nab-paclitaxel","route":"/drugs/nab-paclitaxel/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}